organization · Reporting owner

VHCP Management EG, LLC

Disclosed activity across 4 companies

Tapewire entity: 55707
SEC CIK: 0001808518

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Oruka Therapeutics, Inc.ORKA · Entity 3781	10% owner	February 10, 2025	February 27, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Oruka Therapeutics, Inc.

Report date February 10, 2025 · Filed February 27, 2025

Jointly reported with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Koh Bong Y, Shah Nimish P

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Funds	4,026,120	Reported balance After 2025-02-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-02-10 · Purchase · Acquired 574 · Balance 4,026,120 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.88 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Consists of (i) 835,614 shares held by VHCP3; (ii) 83,701 shares held by VHCP Co-3; and (iii) 3,106,805 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Funds	4,035,713	Reported balance After 2025-02-11 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-02-11 · Purchase · Acquired 9,593 · Balance 4,035,713 F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.86 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F5: Consists of (i) 837,271 shares held by VHCP3; (ii) 83,867 shares held by VHCP Co-3; and (iii) 3,114,575 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Funds	4,044,684	Reported balance After 2025-02-12 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-02-12 · Purchase · Acquired 8,971 · Balance 4,044,684 F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.25 to $12.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F7: Consists of (i) 838,821 shares held by VHCP3; (ii) 84,022 shares held by VHCP Co-3; and (iii) 3,121,841 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Funds	4,059,634	Reported balance After 2025-02-13 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2025-02-13 · Purchase · Acquired 14,950 · Balance 4,059,634 F8: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.31 to $11.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F9: Consists of (i) 841,404 shares held by VHCP3; (ii) 84,280 shares held by VHCP Co-3; and (iii) 3,133,950 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Funds	4,148,428	Reported balance After 2025-02-14 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2025-02-14 · Purchase · Acquired 88,794 · Balance 4,148,428 F10: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.17 to $11.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F11: Consists of (i) 856,747 shares held by VHCP3; (ii) 85,816 shares held by VHCP Co-3; and (iii) 3,205,865 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.88 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F2: Consists of (i) 835,614 shares held by VHCP3; (ii) 83,701 shares held by VHCP Co-3; and (iii) 3,106,805 shares held by VHCP EG.

F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.

F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.86 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F5: Consists of (i) 837,271 shares held by VHCP3; (ii) 83,867 shares held by VHCP Co-3; and (iii) 3,114,575 shares held by VHCP EG.

F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.25 to $12.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F7: Consists of (i) 838,821 shares held by VHCP3; (ii) 84,022 shares held by VHCP Co-3; and (iii) 3,121,841 shares held by VHCP EG.

F8: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.31 to $11.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F9: Consists of (i) 841,404 shares held by VHCP3; (ii) 84,280 shares held by VHCP Co-3; and (iii) 3,133,950 shares held by VHCP EG.

F10: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.17 to $11.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F11: Consists of (i) 856,747 shares held by VHCP3; (ii) 85,816 shares held by VHCP Co-3; and (iii) 3,205,865 shares held by VHCP EG.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

KalVista Pharmaceuticals, Inc.

Report date March 25, 2026 · Filed March 27, 2026

Section 16 reporting ended · disclosed 2026-03-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Funds	5,129,500	Reported balance After 2026-03-25 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-03-25 · Sale · Disposed 174,485 · Balance 5,129,500 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $16.51 to $17.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2: Consists of (i) 1,105,126 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,550 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,913,824 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Funds	5,129,340	Reported balance After 2026-03-25 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-03-25 · Sale · Disposed 160 · Balance 5,129,340 F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.51 to $17.55 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5: Consists of (i) 1,105,092 shares held by VHCP3; (ii) 110,547 shares held by VHCP Co-3; and (iii) 3,913,701 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Funds	5,107,954	Reported balance After 2026-03-26 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-03-26 · Sale · Disposed 21,386 · Balance 5,107,954 F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.07 to $18.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F7: Consists of (i) 1,100,485 shares held by VHCP3; (ii) 110,085 shares held by VHCP Co-3; and (iii) 3,897,384 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Funds	5,092,537	Reported balance After 2026-03-26 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-03-26 · Sale · Disposed 15,417 · Balance 5,092,537 F8: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.07 to $19.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F9: Consists of (i) 1,097,164 shares held by VHCP3; (ii) 109,752 shares held by VHCP Co-3; and (iii) 3,885,621 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Funds	5,089,354	Reported balance After 2026-03-26 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2026-03-26 · Sale · Disposed 3,183 · Balance 5,089,354 F10: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.07 to $19.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F11: Consists of (i) 1,096,478 shares held by VHCP3; (ii) 109,684 shares held by VHCP Co-3; and (iii) 3,883,192 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $16.51 to $17.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F2: Consists of (i) 1,105,126 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,550 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,913,824 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").

F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.51 to $17.55 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F5: Consists of (i) 1,105,092 shares held by VHCP3; (ii) 110,547 shares held by VHCP Co-3; and (iii) 3,913,701 shares held by VHCP EG.

F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.07 to $18.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F7: Consists of (i) 1,100,485 shares held by VHCP3; (ii) 110,085 shares held by VHCP Co-3; and (iii) 3,897,384 shares held by VHCP EG.

F8: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.07 to $19.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F9: Consists of (i) 1,097,164 shares held by VHCP3; (ii) 109,752 shares held by VHCP Co-3; and (iii) 3,885,621 shares held by VHCP EG.

F10: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.07 to $19.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F11: Consists of (i) 1,096,478 shares held by VHCP3; (ii) 109,684 shares held by VHCP Co-3; and (iii) 3,883,192 shares held by VHCP EG.

Tricida, Inc.

Report date October 24, 2022 · Filed October 26, 2022

Jointly reported with Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., Koh Bong Y, Shah Nimish P

Section 16 reporting ended · disclosed 2022-10-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Funds	3,751,406	Last balance in matching sequence After 2022-10-26 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2022-10-24 · Sale · Disposed 2,113,948 · Balance 8,088,998 F1: Consists of (i) 202,708 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), (ii) 82,148 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"), (iii) 617,948 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (iv) 61,806 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (v) 1,149,338 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.59 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Row 2 · 2022-10-25 · Sale · Disposed 1,970,418 · Balance 6,118,580 F4: The shares sold on October 25, 2022 consist of (i) 188,945 shares sold by VHCP II, (ii) 76,569 shares sold by VHCP Co-2, (iii) 575,992 shares sold by VHCP III, (iv) 57,610 shares sold by VHCP Co-3 and (v) 1,071,302 shares sold by VHCP EG. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Row 3 · 2022-10-26 · Sale · Disposed 2,367,174 · Balance 3,751,406 F6: The shares sold on October 26, 2022 consist of (i) 226,991 shares sold by VHCP II, (ii) 91,988 shares sold by VHCP Co-2, (iii) 691,971 shares sold by VHCP III, (iv) 69,208 shares sold by VHCP Co-3 and (v) 1,287,016 shares sold by VHCP EG. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.43 to $0.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of (i) 202,708 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), (ii) 82,148 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"), (iii) 617,948 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (iv) 61,806 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (v) 1,149,338 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.59 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein.

F4: The shares sold on October 25, 2022 consist of (i) 188,945 shares sold by VHCP II, (ii) 76,569 shares sold by VHCP Co-2, (iii) 575,992 shares sold by VHCP III, (iv) 57,610 shares sold by VHCP Co-3 and (v) 1,071,302 shares sold by VHCP EG.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F6: The shares sold on October 26, 2022 consist of (i) 226,991 shares sold by VHCP II, (ii) 91,988 shares sold by VHCP Co-2, (iii) 691,971 shares sold by VHCP III, (iv) 69,208 shares sold by VHCP Co-3 and (v) 1,287,016 shares sold by VHCP EG.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.43 to $0.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Vistagen Therapeutics, Inc.

Report date July 12, 2022 · Filed July 14, 2022

Section 16 reporting ended · disclosed 2022-07-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Funds	20,637,286	Reported balance After 2022-07-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-07-12 · Sale · Disposed 60,000 · Balance 20,637,286 F1: Consists of 14,348 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), 5,814 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP II Co"), 4,688 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), 469 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP III Co") and 34,681 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: Consists of 4,935,020 shares held by VHCP II, 1,999,971 shares held by VHCP II Co, 1,612,582 shares held by VHCP III, 161,351 shares held by VHCP III Co and 11,928,362 shares held by VHCP EG. F4: VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC ("VHCPM EG") is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM II, VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM II, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP II, VHCP II Co, VHCP III, VHCP III Co and VHCP EG, except to the extent of their respective indirect pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of 14,348 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), 5,814 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP II Co"), 4,688 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), 469 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP III Co") and 34,681 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: Consists of 4,935,020 shares held by VHCP II, 1,999,971 shares held by VHCP II Co, 1,612,582 shares held by VHCP III, 161,351 shares held by VHCP III Co and 11,928,362 shares held by VHCP EG.

F4: VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC ("VHCPM EG") is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM II, VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM II, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP II, VHCP II Co, VHCP III, VHCP III Co and VHCP EG, except to the extent of their respective indirect pecuniary interests therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 26, 2026 Filed Mar 27, 2026 17:50 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	SaleCommon Stock	3,183	$19.12	$60,858.96	Disclosure SEC source: 0001231919-26-000286 · form4-03272026_090302.xml · nonDerivative · entry 5 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,089,354 F10 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.07 to $19.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F11 · balance_after: Consists of (i) 1,096,478 shares held by VHCP3; (ii) 109,684 shares held by VHCP Co-3; and (iii) 3,883,192 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
March 26, 2026 Filed Mar 27, 2026 17:50 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	SaleCommon Stock	15,417	$18.82	$290,147.94	Disclosure SEC source: 0001231919-26-000286 · form4-03272026_090302.xml · nonDerivative · entry 4 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,092,537 F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.07 to $19.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F9 · balance_after: Consists of (i) 1,097,164 shares held by VHCP3; (ii) 109,752 shares held by VHCP Co-3; and (iii) 3,885,621 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
March 26, 2026 Filed Mar 27, 2026 17:50 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	SaleCommon Stock	21,386	$17.76	$379,815.36	Disclosure SEC source: 0001231919-26-000286 · form4-03272026_090302.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,107,954 F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.07 to $18.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 1,100,485 shares held by VHCP3; (ii) 110,085 shares held by VHCP Co-3; and (iii) 3,897,384 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
March 25, 2026 Filed Mar 27, 2026 17:50 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	SaleCommon Stock	160	$17.53	$2,804.80	Disclosure SEC source: 0001231919-26-000286 · form4-03272026_090302.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,129,340 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.51 to $17.55 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 1,105,092 shares held by VHCP3; (ii) 110,547 shares held by VHCP Co-3; and (iii) 3,913,701 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
March 25, 2026 Filed Mar 27, 2026 17:50 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	SaleCommon Stock	174,485	$16.95	$2,957,520.75	Disclosure SEC source: 0001231919-26-000286 · form4-03272026_090302.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,129,500 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $16.51 to $17.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 1,105,126 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,550 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,913,824 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
April 09, 2025 Filed Apr 11, 2025 17:22 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	25,000	$9.42	$235,500.00	Disclosure SEC source: 0001415889-25-010587 · form4-04112025_090402.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,303,985 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.27 to $9.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 1,142,719 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 114,312 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 4,046,954 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 14, 2025 Filed Feb 27, 2025 18:42 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	PurchaseCommon Stock	88,794	$11.44	$1,015,803.36	Disclosure SEC source: 0001415889-25-005908 · form4-02272025_110244.xml · nonDerivative · entry 5 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,148,428 F10 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.17 to $11.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F11 · balance_after: Consists of (i) 856,747 shares held by VHCP3; (ii) 85,816 shares held by VHCP Co-3; and (iii) 3,205,865 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 13, 2025 Filed Feb 14, 2025 19:45 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	61,700	$9.33	$575,661.00	Disclosure SEC source: 0001415889-25-004324 · form4-02152025_120211.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,278,985 F4 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.01 to $9.35 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 1,137,549 shares held by VHCP3; (ii) 113,795 shares held by VHCP Co-3; and (iii) 4,027,641 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 13, 2025 Filed Feb 27, 2025 18:42 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	PurchaseCommon Stock	14,950	$11.63	$173,868.50	Disclosure SEC source: 0001415889-25-005908 · form4-02272025_110244.xml · nonDerivative · entry 4 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,059,634 F8 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.31 to $11.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F9 · balance_after: Consists of (i) 841,404 shares held by VHCP3; (ii) 84,280 shares held by VHCP Co-3; and (iii) 3,133,950 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 12, 2025 Filed Feb 14, 2025 19:45 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	100,000	$9.23	$923,000.00	Disclosure SEC source: 0001415889-25-004324 · form4-02152025_120211.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,217,285 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.15 to $9.30 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 1,126,887 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 112,728 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,977,670 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 12, 2025 Filed Feb 27, 2025 18:42 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	PurchaseCommon Stock	8,971	$11.86	$106,396.06	Disclosure SEC source: 0001415889-25-005908 · form4-02272025_110244.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,044,684 F6 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.25 to $12.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 838,821 shares held by VHCP3; (ii) 84,022 shares held by VHCP Co-3; and (iii) 3,121,841 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 11, 2025 Filed Feb 11, 2025 19:51 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	26,703	$9.18	$245,133.54	Disclosure SEC source: 0001415889-25-003665 · form4-02122025_120203.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,117,285 F6 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.07 to $9.21 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 1,109,607 shares held by VHCP3; (ii) 110,998 shares held by VHCP Co-3; and (iii) 3,896,680 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 11, 2025 Filed Feb 27, 2025 18:42 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	PurchaseCommon Stock	9,593	$10.95	$105,043.35	Disclosure SEC source: 0001415889-25-005908 · form4-02272025_110244.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,035,713 F4 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.86 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 837,271 shares held by VHCP3; (ii) 83,867 shares held by VHCP Co-3; and (iii) 3,114,575 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 10, 2025 Filed Feb 11, 2025 19:51 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	4,137	$9.14	$37,812.18	Disclosure SEC source: 0001415889-25-003665 · form4-02122025_120203.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,090,582 F4 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.11 to $9.17 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 1,104,993 shares held by VHCP3; (ii) 110,536 shares held by VHCP Co-3; and (iii) 3,875,053 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 10, 2025 Filed Feb 27, 2025 18:42 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	PurchaseCommon Stock	574	$10.90	$6,256.60	Disclosure SEC source: 0001415889-25-005908 · form4-02272025_110244.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,026,120 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.88 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 835,614 shares held by VHCP3; (ii) 83,701 shares held by VHCP Co-3; and (iii) 3,106,805 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 07, 2025 Filed Feb 11, 2025 19:51 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	73,649	$9.29	$684,199.21	Disclosure SEC source: 0001415889-25-003665 · form4-02122025_120203.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,086,445 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.15 to $9.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 1,104,278 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,465 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,871,702 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 03, 2025 Filed Feb 3, 2025 19:42 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	14,562	$9.22	$134,261.64	Disclosure SEC source: 0001415889-25-002809 · form4-02042025_120255.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 5,012,796 F6 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.08 to $9.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 1,091,552 shares held by VHCP3; (ii) 109,191 shares held by VHCP Co-3; and (iii) 3,812,053 shares held by VHCP EG. Read SEC document
January 31, 2025 Filed Feb 3, 2025 19:42 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	11,754	$8.89	$104,493.06	Disclosure SEC source: 0001415889-25-002809 · form4-02042025_120255.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,998,234 F4 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $8.70 to $9.09 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 1,089,036 shares held by VHCP3; (ii) 108,939 shares held by VHCP Co-3; and (iii) 3,800,259 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 30, 2025 Filed Feb 3, 2025 19:42 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	43,707	$8.76	$382,873.32	Disclosure SEC source: 0001415889-25-002809 · form4-02042025_120255.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,986,480 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $8.74 to $8.91 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 1,087,005 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 108,736 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,790,739 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 20, 2024 Filed Feb 22, 2024 16:15 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchasePre-Funded Warrants (Right to Buy) · Derivative	655,738	$15.25 Strike: $0.00	$9,999,348.76	Disclosure SEC source: 0001415889-24-004790 · form4-02222024_040201.xml · derivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 655,738 Underlying: Common Stock · 655,738 shares Expires not disclosed F1 · shares: Consists of (i) 172,394 securities held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 17,246 securities held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 466,098 securities held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F2 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F2 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. F1 · derivative.underlying_shares: Consists of (i) 172,394 securities held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 17,246 securities held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 466,098 securities held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F1 · balance_after: Consists of (i) 172,394 securities held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 17,246 securities held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 466,098 securities held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 08, 2024 Filed Feb 8, 2024 20:11 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	29,747	$14.70	$437,280.90	Disclosure SEC source: 0001415889-24-003118 · form4-02092024_010228.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,824,731 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.53 to $14.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 1,059,054 shares held by VHCP3; (ii) 105,940 shares held by VHCP Co-3; and (iii) 3,659,737 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 07, 2024 Filed Feb 8, 2024 20:11 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	51,827	$14.56	$754,601.12	Disclosure SEC source: 0001415889-24-003118 · form4-02092024_010228.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,794,984 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.41 to $14.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 1,051,233 shares held by VHCP3; (ii) 105,158 shares held by VHCP Co-3; and (iii) 3,638,593 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
February 06, 2024 Filed Feb 8, 2024 20:11 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	4,474	$14.74	$65,946.76	Disclosure SEC source: 0001415889-24-003118 · form4-02092024_010228.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,743,157 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.70 to $14.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 1,037,607 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 103,796 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,601,754 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 30, 2024 Filed Feb 1, 2024 16:38 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	88,099	$14.47	$1,274,792.53	Disclosure SEC source: 0001415889-24-002183 · form4-02012024_090237.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,738,683 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.25 to $14.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 1,036,431 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 103,678 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,598,574 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 29, 2024 Filed Jan 29, 2024 19:07 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	80,600	$14.22	$1,146,132.00	Disclosure SEC source: 0001415889-24-001941 · form4-01302024_120108.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,650,584 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.51 to $14.43 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 1,013,271 shares held by VHCP3; (ii) 101,361 shares held by VHCP Co-3; and (iii) 3,535,952 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 26, 2024 Filed Jan 29, 2024 19:07 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	4,174	$12.98	$54,178.52	Disclosure SEC source: 0001415889-24-001941 · form4-01302024_120108.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,569,984 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.96 to $12.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 992,081 shares held by VHCP3; (ii) 99,242 shares held by VHCP Co-3; and (iii) 3,478,661 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 25, 2024 Filed Jan 29, 2024 19:07 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	7,030	$12.73	$89,491.90	Disclosure SEC source: 0001415889-24-001941 · form4-01302024_120108.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,565,810 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.64 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 990,984 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 99,132 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,475,694 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 24, 2024 Filed Jan 24, 2024 20:24 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	20,686	$12.44	$257,333.84	Disclosure SEC source: 0001415889-24-001781 · form4-01252024_010153.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,558,780 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.15 to $12.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 989,136 shares held by VHCP3; (ii) 98,947 shares held by VHCP Co-3; and (iii) 3,470,697 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 23, 2024 Filed Jan 24, 2024 20:24 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	10,897	$12.54	$136,648.38	Disclosure SEC source: 0001415889-24-001781 · form4-01252024_010153.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,538,094 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.52 to $12.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 983,698 shares held by VHCP3; (ii) 98,403 shares held by VHCP Co-3; and (iii) 3,455,993 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 22, 2024 Filed Jan 24, 2024 20:24 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	67,546	$12.55	$847,702.30	Disclosure SEC source: 0001415889-24-001781 · form4-01252024_010153.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,527,197 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.37 to $12.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 980,833 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 98,117 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,448,247 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 19, 2024 Filed Jan 19, 2024 18:02 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	25,000	$12.43	$310,750.00	Disclosure SEC source: 0001209191-24-001957 · doc4.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,459,651 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.21 to $12.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 980,833 shares held by VHCP3; (ii) 98,117 shares held by VHCP Co-3; and (iii) 3,380,701 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 18, 2024 Filed Jan 19, 2024 18:02 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	39,680	$12.51	$496,396.80	Disclosure SEC source: 0001209191-24-001957 · doc4.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,434,651 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.40 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 980,833 shares held by VHCP3; (ii) 98,117 shares held by VHCP Co-3; and (iii) 3,355,701 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 17, 2024 Filed Jan 19, 2024 18:02 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	78,925	$12.60	$994,455.00	Disclosure SEC source: 0001209191-24-001957 · doc4.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,394,971 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.53 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 970,401 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 97,074 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3"); and (iii) 3,327,496 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 16, 2024 Filed Jan 16, 2024 19:04 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	19,599	$12.73	$249,495.27	Disclosure SEC source: 0001209191-24-001666 · doc4.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,316,046 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.59 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 949,652 shares held by VHCP3; (ii) 94,999 shares held by VHCP Co-3; and (iii) 3,271,395 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 11, 2024 Filed Jan 16, 2024 19:04 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	6,647	$12.68	$84,283.96	Disclosure SEC source: 0001209191-24-001666 · doc4.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,296,447 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.55 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 944,499 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 94,484 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3"); and (iii) 3,257,464 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 10, 2024 Filed Jan 10, 2024 20:57 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	47,700	$12.67	$604,359.00	Disclosure SEC source: 0001209191-24-001403 · doc4.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,289,800 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.40 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 942,752 shares held by VHCP3; (ii) 94,309 shares held by VHCP Co-3; and (iii) 3,252,739 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 09, 2024 Filed Jan 10, 2024 20:57 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	20,816	$12.56	$261,448.96	Disclosure SEC source: 0001209191-24-001403 · doc4.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,242,100 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.35 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 930,212 shares held by VHCP3; (ii) 93,054 shares held by VHCP Co-3; and (iii) 3,218,834 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 08, 2024 Filed Jan 10, 2024 20:57 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	69,184	$12.44	$860,648.96	Disclosure SEC source: 0001209191-24-001403 · doc4.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,221,284 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 924,739 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 92,507 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3"); and (iii) 3,204,038 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 04, 2024 Filed Jan 5, 2024 16:13 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	41,764	$12.11	$505,762.04	Disclosure SEC source: 0001209191-24-001008 · doc4.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,152,100 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.91 to $12.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 906,551 shares held by VHCP3; (ii) 90,687 shares held by VHCP Co-3; and (iii) 3,154,862 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
January 03, 2024 Filed Jan 5, 2024 16:13 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	17,605	$12.20	$214,781.00	Disclosure SEC source: 0001209191-24-001008 · doc4.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,110,336 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.08 to $12.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 895,571 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 89,587 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3"); and (iii) 3,125,178 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
December 29, 2023 Filed Dec 29, 2023 18:44 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	6,013	$12.49	$75,102.37	Disclosure SEC source: 0001209191-23-060015 · doc4.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,092,731 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.44 to $12.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F7 · balance_after: Consists of (i) 890,943 shares held by VHCP3; (ii) 89,124 shares held by VHCP Co-3; and (iii) 3,112,664 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
December 28, 2023 Filed Dec 29, 2023 18:44 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	471,490	$12.50	$5,893,625.00	Disclosure SEC source: 0001209191-23-060015 · doc4.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 4,086,718 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.88 to $12.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Consists of (i) 889,362 shares held by VHCP3; (ii) 88,966 shares held by VHCP Co-3; and (iii) 3,108,390 shares held by VHCP EG. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
December 27, 2023 Filed Dec 29, 2023 18:44 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	PurchaseCommon Stock	41,514	$11.97	$496,922.58	Disclosure SEC source: 0001209191-23-060015 · doc4.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Funds Disclosed balance after: 3,615,228 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.68 to $12.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Consists of (i) 856,000 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 85,630 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3"); and (iii) 2,673,598 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein. Read SEC document
October 26, 2022 Filed Oct 26, 2022 18:32 UTC	Tricida, Inc. TCDA · Entity 122050	SaleCommon Stock	2,367,174	$0.46	$1,088,900.04	Disclosure SEC source: 0001209191-22-054671 · doc4.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 3,751,406 F6 · shares: The shares sold on October 26, 2022 consist of (i) 226,991 shares sold by VHCP II, (ii) 91,988 shares sold by VHCP Co-2, (iii) 691,971 shares sold by VHCP III, (iv) 69,208 shares sold by VHCP Co-3 and (v) 1,287,016 shares sold by VHCP EG. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.43 to $0.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Read SEC document
October 25, 2022 Filed Oct 26, 2022 18:32 UTC	Tricida, Inc. TCDA · Entity 122050	SaleCommon Stock	1,970,418	$0.57	$1,123,138.26	Disclosure SEC source: 0001209191-22-054671 · doc4.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 6,118,580 F4 · shares: The shares sold on October 25, 2022 consist of (i) 188,945 shares sold by VHCP II, (ii) 76,569 shares sold by VHCP Co-2, (iii) 575,992 shares sold by VHCP III, (iv) 57,610 shares sold by VHCP Co-3 and (v) 1,071,302 shares sold by VHCP EG. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Read SEC document
October 24, 2022 Filed Oct 26, 2022 18:32 UTC	Tricida, Inc. TCDA · Entity 122050	SaleCommon Stock	2,113,948	$0.61	$1,289,508.28	Disclosure SEC source: 0001209191-22-054671 · doc4.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 8,088,998 F1 · shares: Consists of (i) 202,708 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), (ii) 82,148 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"), (iii) 617,948 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (iv) 61,806 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (v) 1,149,338 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.59 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Read SEC document
October 19, 2022 Filed Oct 20, 2022 17:25 UTC	Tricida, Inc. TCDA · Entity 122050	PurchaseCommon Stock	70,100	$11.25	$788,625.00	Disclosure SEC source: 0001209191-22-054201 · doc4.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 10,202,946 F4 · shares: The shares purchased on October 19, 2022 consist of (i) 81,884 shares purchased by VHCP III, (ii) 8,192 shares purchased by VHCP Co-3 and (iii) 221,390 shares purchased by VHCP EG. F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Read SEC document
October 19, 2022 Filed Oct 20, 2022 17:25 UTC	Tricida, Inc. TCDA · Entity 122050	PurchaseCommon Stock	241,366	$10.29	$2,483,656.14	Disclosure SEC source: 0001209191-22-054201 · doc4.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 10,132,846 F4 · shares: The shares purchased on October 19, 2022 consist of (i) 81,884 shares purchased by VHCP III, (ii) 8,192 shares purchased by VHCP Co-3 and (iii) 221,390 shares purchased by VHCP EG. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Read SEC document
October 18, 2022 Filed Oct 20, 2022 17:25 UTC	Tricida, Inc. TCDA · Entity 122050	PurchaseCommon Stock	40,400	$11.98	$483,992.00	Disclosure SEC source: 0001209191-22-054201 · doc4.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 9,891,480 F1 · shares: Consists of (i) 10,621 shares purchased by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (ii) 1,062 shares purchased by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (iii) 28,717 shares purchased by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.97 to $12.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Read SEC document
October 17, 2022 Filed Oct 17, 2022 17:26 UTC	Tricida, Inc. TCDA · Entity 122050	PurchaseCommon Stock	170,292	$11.67	$1,987,307.64	Disclosure SEC source: 0001209191-22-053863 · doc4.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners EG, L.P. · CIK 0001808512 · 10% owner VHCP Management EG, LLC · CIK 0001808518 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 9,851,080 F4 · shares: Consists of (i) 44,770 shares purchased by VHCP III, (ii) 4,479 shares purchased by VHCP Co-3 and (iii) 121,043 shares purchased by VHCP EG. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.57 to $11.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.